Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma

Witjes JA, Bruins HM, Carrión A, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer. Arnhem, The Netherlands: European Association of Urology; 2023. https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer. Powles, 2022, Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment, and follow-up, Ann Oncol, 33, 244, 10.1016/j.annonc.2021.11.012 Friedlander, 2023, Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): additional 3-month follow-up on cohort K data, J Clin Oncol, 41, 4568, 10.1200/JCO.2023.41.16_suppl.4568 Merck. FDA approves Merck’s KEYTRUDA® (pembrolizumab) in combination with Padcev® (enfortumab vedotin-ejfv) for first-line treatment of certain patients with locally advanced or metastatic urothelial cancer. Rahway, NJ: Merck and Co. Inc.; April 3, 2023 https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-padcev-enfortumab-vedotin-ejfv-for-first-line-treatment-of-certain-patients-with-locally-advanced-or-metastatic/. Powles, 2020, Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma, N Engl J Med, 383, 1218, 10.1056/NEJMoa2002788 Cheeseman, 2020, Current treatment and outcomes benchmark for locally advanced or metastatic urothelial cancer from a large UK-based single centre, Front Oncol, 10, 167, 10.3389/fonc.2020.00167 Galsky, 2020, Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial, Lancet, 395, 1547, 10.1016/S0140-6736(20)30230-0 Galsky, 2023, Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem for first-line (1L) treatment (tx) of locally advanced or metastatic urothelial carcinoma (mUC): final OS from the randomized phase 3 IMvigor130 study, J Clin Oncol, 41, LBA440, 10.1200/JCO.2023.41.6_suppl.LBA440 Grande, 2021, Cancer Res, 81, CT187, 10.1158/1538-7445.AM2021-CT187 Galsky, 2021, Cisplatin (cis)-related immunomodulation and efficacy with atezolizumab (atezo) + cis- vs carboplatin (carbo)-based chemotherapy (chemo) in metastatic urothelial cancer (mUC), Ann Oncol, 32, S682, 10.1016/j.annonc.2021.08.054